Oncology Results Can Be Clearer If Trials Target Early Stages – FDA’s Pazdur
Executive Summary
Oncology drug developers should conduct randomized trials in less heavily pre-treated patients to gain a clearer picture of the drug's efficacy, FDA Oncology Division Director Richard Pazdur said
You may also be interested in...
FDA Asks ODAC To Ponder Shift Away From Single-Arm Studies
At its Feb. 8 meeting on issues surrounding confirmatory post-marketing studies, the Oncologic Drugs Advisory Committee will discuss whether and when randomized studies should be required to secure accelerated approval.
Context Is Key To Accelerated Approval In Oncology, Arzerra Review Shows
By targeting a population with an unmet medical need that would qualify for review under FDA's accelerated approval regulations, GlaxoSmithKline and Genmab transcended a "suboptimal" development program and "uncertainty" regarding the magnitude of treatment effect to bring their anti-CD20 monoclonal antibody Arzerra (ofatumumab) to market, FDA review documents show
Context Is Key To Accelerated Approval In Oncology, Arzerra Review Shows
By targeting a population with an unmet medical need that would qualify for review under FDA's accelerated approval regulations, GlaxoSmithKline and Genmab transcended a "suboptimal" development program and "uncertainty" regarding the magnitude of treatment effect to bring their anti-CD20 monoclonal antibody Arzerra (ofatumumab) to market, FDA review documents show